Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30567753

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2019 Jan 31
First author
Grommes C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Grommes C
      type
      Author
    2. name
      Tang SS
      type
      Author
    3. name
      Wolfe J
      type
      Author
    4. name
      Kaley TJ
      type
      Author
    5. name
      Daras M
      type
      Author
    6. name
      Pentsova EI
      type
      Author
    7. name
      Piotrowski AF
      type
      Author
    8. name
      Stone J
      type
      Author
    9. name
      Lin A
      type
      Author
    10. name
      Nolan CP
      type
      Author
    11. name
      Manne M
      type
      Author
    12. name
      Codega P
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Grommes C
      type
      Author
    2. name
      Tang SS
      type
      Author
    3. name
      Wolfe J
      type
      Author
    4. name
      Kaley TJ
      type
      Author
    5. name
      Daras M
      type
      Author
    6. name
      Pentsova EI
      type
      Author
    7. name
      Piotrowski AF
      type
      Author
    8. name
      Stone J
      type
      Author
    9. name
      Lin A
      type
      Author
    10. name
      Nolan CP
      type
      Author
    11. name
      Manne M
      type
      Author
    12. name
      Codega P
      type
      Author
    bibliography ids
    1. nci-bib-323641062de5464d41a3d7ec
    book metadata
    content sha256
    255338c692764e4454d6ca3ded3b061f3078e4f06420fe1799c329001906da15
    document type
    citation
    dois
    1. 10.1182/blood-2018-09-875732
    electronic publication date
    display
    2018 Dec 19
    precision
    day
    year
    2018
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:30567753
    immutable id
    pubmed:30567753@255338c692764e4454d6ca3ded3b061f3078e4f06420fe1799c329001906da15
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    5
    name
    Blood
    nlm unique id
    7603509
    pages
    436-445
    volume
    133
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      30567753
      provenance
      batch id
      e808962322f3afebc564
      provider
      NCBI PubMed ESummary
      record sha256
      688a773a8ad6b43def25b0c5ac47c613ffcfc9cf79540cfc4970e77cc59f433a
      response sha256
      3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
      retrieved at
      2026-09-09T23:47:41.002093+00:00
      publication date
      display
      2019 Jan 31
      precision
      day
      year
      2019
      publication types
      1. Clinical Trial, Phase I
      2. Journal Article
      3. Research Support, N.I.H., Extramural
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/30567753/
      title
      Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

      Preserved source evidence · Not medical advice